Nano-X Imaging (NNOX) Projected to Post Earnings on Monday

Key Points

• Nano‑X Imaging is expected to report Q4 2025 results before the market opens on March 30, 2026, with analysts forecasting a loss of ($0.15) per share and revenue of $3.994 million; an earnings call is scheduled for March 31 at 12:30 PM ET.
• The stock opened at $2.41, trades in a 12‑month range of $2.11–$6.22 with a market cap of $157.6M, a negative P/E of -1.83, and 50-/200‑day moving averages of $2.64 and $3.27, respectively.
• Analyst sentiment is mixed but tilts positive—three Strong Buy, one Buy and one Sell produce an average "Buy" consensus with a $7.00 target—while institutional investors own about 21.49% of the stock, including sizable recent stake increases by UBS and others.

Nano-X Imaging (NASDAQ:NNOX - Get Free Report) is anticipated to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Nano-X Imaging to post earnings of ($0.15) per share and revenue of $3.9940 million for the quarter. Investors may review the information on the company's upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 31, 2026 at 12:30 PM ET.

Nano-X Imaging Stock Performance

NASDAQ NNOX opened at $2.41 on Monday. Nano-X Imaging has a twelve month low of $2.11 and a twelve month high of $6.22. The stock has a market cap of $157.57 million, a price-to-earnings ratio of -1.83 and a beta of 1.38. The firm's 50 day moving average price is $2.64 and its two-hundred day moving average price is $3.27.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on NNOX shares. D. Boral Capital reaffirmed a "buy" rating and issued a $5.00 target price on shares of Nano-X Imaging in a research report on Tuesday, March 3rd. Cantor Fitzgerald raised Nano-X Imaging to a "strong-buy" rating in a research report on Wednesday, March 4th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Nano-X Imaging in a research note on Monday, December 29th. Three analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $7.00.

Hedge Funds Weigh In On Nano-X Imaging

Institutional investors and hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC purchased a new stake in shares of Nano-X Imaging during the first quarter worth $178,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Nano-X Imaging by 232.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,160,806 shares of the company's stock valued at $10,793,000 after purchasing an additional 1,510,806 shares in the last quarter. Geode Capital Management LLC grew its stake in Nano-X Imaging by 17.5% in the second quarter. Geode Capital Management LLC now owns 810,322 shares of the company's stock valued at $4,189,000 after purchasing an additional 120,460 shares in the last quarter. Cetera Investment Advisers increased its position in Nano-X Imaging by 82.0% in the 2nd quarter. Cetera Investment Advisers now owns 48,056 shares of the company's stock worth $248,000 after purchasing an additional 21,657 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in Nano-X Imaging by 61.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 65,783 shares of the company's stock worth $340,000 after purchasing an additional 25,048 shares during the last quarter. 21.49% of the stock is currently owned by hedge funds and other institutional investors.

About Nano-X Imaging

Nano-X Imaging Ltd. is a medical technology company developing and commercializing a digital X-ray imaging platform designed to lower the cost and increase the accessibility of diagnostic imaging. Its flagship product, the Nanox.ARC, leverages a proprietary micro-electromechanical system (MEMS) based digital X-ray source and advanced image processing software to provide 2D and 3D imaging capabilities on a compact footprint. The system aims to streamline radiology workflows and facilitate point-of-care diagnostics in hospitals, clinics and outpatient settings.

The Nanox.ARC platform integrates a novel cold cathode X-ray source, which enables multiple emission points without the need for rotating anode tubes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.